FABP5 and urothelial carcinoma: The aim of the present study was to investigate by immunohistochemistry the expression of E-FABP in a cohort of 210 patients with urothelial carcinoma (UC) of different stages (pTa, pT1, pT2-T4) and grades (PUNLMP, low grade, high grade) to evaluate whether it could be associated with clinicopathological parameters (grade, stage, ...), and it could help predict disease recurrence and or/progression in pTa and pT1 patient groups after TUR.